SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Other current liabilities:      
Director fees $ 25 $ 11  
Trade payables 41 29  
Accrued expenses and other 160 144  
Other current liabilities 226 184  
Financial expenses:      
Loss from change in fair value of investment in BioCancell and sale of BioCancell shares (36) (245)
Other (2) (7)
Financial expenses $ (38) $ (252)
Financial income:      
Income from change in fair value of investment in BioCancell and sale of BioCancell shares $ 574
Other $ 9 $ 12 5
Financial income 9 12 579
Financial income (expenses), net $ (29) $ (240) $ 579